UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: August 2024
Commission File Number: 001-39152
QUANTUM BIOPHARMA LTD. |
(Translation of registrant's name into English) |
199 Bay St., Suite 4000
Toronto, Ontario M5L 1A9, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INCORPORATION BY REFERENCE
This Form 6-K and Exhibit 99.1 attached hereto are incorporated by reference into the Registrant’s Registration Statement on Form F-3 (SEC File No. 333-276264), including any prospectuses forming a part of such Registration Statement.
EXPLANATORY NOTE
On August 23, 2024, Quantum Biopharma Ltd. issued a press release titled “Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference into this Form 6-K.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Quantum BioPharma Ltd. (Registrant) |
| |
|
|
|
|
Date: August 23, 2024 | By: | /s/ Nathan Coyle |
|
|
| Nathan Coyle, Chief Financial Officer |
|
| 3 |
EXHIBIT INDEX
Exhibit |
| Description |
|
|
|
|
| 4 |